Breaking news & trusted journalism for your community
Opinion
Restaurant Brands International on Thursday reported quarterly earnings that topped analysts' expectations, fueled by strong growth for the once-struggling Burger King, both domestically and abroad.
Opinion
Peloton delivered its first full year of net profit and operating income in fiscal 2026, but said it expects sales to fall in the coming fiscal year as it begins to lap price increases on its hardware and subscription p…
Opinion
Shares of adtech giant Applovin tanked 17% on Thursday following a second-quarter revenue miss.
Opinion
Gold is glittering, and it is time to make the most of it. While last year was a strong year for the precious metal, and has started 2026 even stronger. And after a recent pullback, prices have recovered with the market…
Opinion
Rheinmetall on Thursday trimmed its 2026 guidance after a cancelled project to make large warships for the German government fell through earlier this year.
Opinion
E.l.f. Beauty's profits nearly doubled during its fiscal first quarter thanks to a windfall of cash it received in tariff refunds from the federal government, the company said Wednesday.
Opinion
Disney parks are defying a slump in international travel to the U.S., posting record quarterly revenue for the company's experiences division on Wednesday.
Opinion
The strength of its GLP-1 business suggests the stock still has more room to run.
Opinion
CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.
Opinion
Disney reported growth at its domestic theme parks and cruises despite mounting macroeconomic uncertainty for consumers.
Opinion
Tanger CEO Stephen Yalof said the store operator saw traffic increase in June and July due to international and domestic tourism tied to the World Cup.
Opinion
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro…
Opinion
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Opinion
The market thrilled with SpaceX's first-ever earnings report — but big slide on Wednesday might be a buy-the-dip opportunity for investors based on what Wall Street analysts are saying about their outlook.
Opinion
In addressing Wall Street for the first time since SpaceX's IPO, executives tried to make the case that hefty AI investments are paying off within a year.
Opinion
U.S.-traded shares of Novo Nordisk dropped about 6% on Tuesday after the Danish drugmaker released guidance that appeared to disappoint investors.
Opinion
Not only did results outpace expectations on both the top and bottom lines, but we also got a boost to full-year guidance.
Opinion
Lucid Group missed Wall Street's second-quarter expectations as the electric vehicle manufacturer conducts an "operational reset" amid leadership changes and cost-cutting efforts.
Opinion
DuPont's results and guidance aren't as bad as the market's initial reaction suggested.
Opinion
Most investors start their stock search by chasing what’s already working. They scan for the biggest gainers, follow headlines about hot sectors, or buy whatever name keeps appearing in their social media feed.
Opinion
Saudi Aramco on Tuesday reported a jump in second-quarter profit, following a period of severe disruption through the Strait of Hormuz amid the sprawling Middle East conflict.
Opinion
Oil prices turn lower as Bessent says U.S. may have Iran deal "today or tomorrow"
Opinion
Oil prices turn lower as Bessent says U.S. may have Iran deal "today or tomorrow"
Opinion
Gold has corrected sharply after its best two-year run in decades, but the secular bull market remains in place.